Amoéba

Regulatory Filings • Nov 3, 2022

PRESS RELEASE

US EPA approves Amoeba's biocontrol solution for agricultural use

Lyon (France), November 3, 2022 – 8.45 am- AMOÉBA (FR0011051598 - ALMIB), producer of a biological biocide capable of eliminating bacterial risk in water and human wounds, and of a biocontrol product for plant protection, still in development phase, informs that the US Environmental Protection Agency (US EPA) has approved the use of the lysate of Willaertia magna C2c Maky as an active substance for use in plant protection.

As a result of the EPA's favorable pre-decision (see Press Release dated September 29th, 2022), the lysate of the amoeba Willaertia magna C2c Maky is now approved for use in the United States for the control of fungal plant diseases in agriculture.

In accordance with the pre-decision, the US EPA has confirmed the exemption of Willaertia magna C2c Maky lysate from maximum residue limits (see Press Release dated October 12th, 2022) and exemption of pre-harvest intervals when applied in accordance with instructions for use and good agricultural practices.

Formulations (products) containing Willaertia magna C2c Maky lysate will be subject to an application for marketing authorization to the EPA in 2023, with an approval expected in 2024.

About Amoéba:

Founded in 2010, Amoéba is a French company, based in Chassieu (Lyon, France), specialised in the treatment of microbiological risk in natural resources. Over the last ten years, Amoéba has developed a triple scientific, industrial and commercial expertise around the amoeba Willaertia magna C2c Maky. This biological solution is an alternative to the chemical products widely used today. Amoéba is currently focusing on the biocontrol market for plant protection, estimated at €1.6 billion (1), as well as on the US market for industrial water treatment in closed circuits. In the long term, the Company plans to develop new applications such as the treatment of chronic wounds, valued at €751 million (2) in the United States. The commercialisation of crop protection, biocides and healthcare products is subject to local regulatory approvals. The company is currently testing the biocontrol application for plant protection and does not market any products.

Amoéba is listed on Euronext Growth. The Company is a member of the BPI Excellence network and is eligible for the PEA-PME scheme. More information on www.amoeba-nature.com.

1. marketsandmarkets.com, "Wound Care Market by Product, Wound Type, End User - Global Forecast to 2021," 2016.

2.Amoéba data

Contacts: Amoéba Valérie FILIATRE Deputy General Manager +33 4 26 69 16 00 v.filiatre@amoeba-nature.com

Calyptus Investor & Press Relations Nicolas HELIN / Mathieu CALLEUX +33 1 53 65 37 90 /91 amoeba@calyptus.net

Tel: +33 (0)4 26 69 16 00 – Email: contact@amoeba-nature.com Linkedin: @amoeba-nature – Twitter: @AmoebaNature www.amoeba-nature.com

Disclaimer

This press release contains certain forward-looking statements concerning AMOEBA which are based on its own assumptions and hypothesis and on information that are available to us. However, AMOEBA gives no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the reference document of AMOEBA filed with the French Financial Markets Authority (Autorité des Marchés Financiers) on April 12, 2022 under number D22-0280 and available on the AMOÉBA website (www.amoeba-nature.com). The forward-looking statements contained in this press release are also subject to risks not yet known to AMOEBA or not currently considered material by AMOEBA. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of AMOEBA to be materially different from such forwardlooking statements.